Preverna Inc. develops Chimeric Adapter Proteins (CAP-T™) for the treatment of solid tumors, utilizing a unique intracellular signaling mechanism to enhance the efficacy of immunotherapy. This technology aims to provide personalized and more effective treatment options for cancer patients, addressing the limitations of current therapies in targeting solid tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Current immunotherapy treatments often struggle to effectively target and eliminate solid tumors due to the tumor microenvironment and limited penetration of immune cells. Existing cell therapies may lack the necessary signaling mechanisms to fully activate and direct immune responses within the tumor. This results in suboptimal efficacy and limited treatment options for patients with solid tumor cancers.
Solution
Preverna Inc. is developing Chimeric Adapter Proteins (CAP-T™) cell therapies designed to enhance the efficacy of immunotherapy against solid tumors. CAP-T™ technology utilizes a unique intracellular signaling mechanism to improve the ability of immune cells to recognize, infiltrate, and destroy cancer cells within the tumor microenvironment. By modifying immune cells with CAP-T™, the therapy aims to create a more robust and targeted immune response, leading to improved outcomes for patients with solid tumors. This approach seeks to overcome the limitations of current immunotherapies by providing a personalized and more effective treatment option.
Target Audience
The primary target audience includes cancer patients with solid tumors who are seeking more effective and personalized immunotherapy options, as well as oncologists and medical professionals specializing in cancer treatment.
Features
- CAP-T™ technology employs a novel intracellular signaling pathway distinct from traditional approaches.
- Designed to enhance immune cell infiltration into solid tumors.
- Aims to improve the recognition and elimination of cancer cells by the immune system.
- Seeks to provide a more personalized and effective treatment option for solid tumor cancers.
- In vivo and in vitro data supports the transformative potential of CAP-T™ technology.